Efficacy and safety of COVID-19 vaccines: A network meta-analysis.

Autor: Toubasi AA; Faculty of Medicine, University of Jordan, Amman, Jordan., Al-Sayegh TN; Faculty of Medicine, University of Jordan, Amman, Jordan., Obaid YY; Faculty of Medicine, University of Jordan, Amman, Jordan., Al-Harasis SM; Faculty of Medicine, University of Jordan, Amman, Jordan., AlRyalat SAS; Department of Ophthalmology, University of Jordan, Amman, Jordan.
Jazyk: angličtina
Zdroj: Journal of evidence-based medicine [J Evid Based Med] 2022 Sep; Vol. 15 (3), pp. 245-262. Date of Electronic Publication: 2022 Aug 23.
DOI: 10.1111/jebm.12492
Abstrakt: Objective: Several vaccines showed a good safety profile and significant efficacy against COVID-19. Moreover, in the absence of direct head to head comparison between COVID-19 vaccines, a network meta-analysis that indirectly compares between them is needed.
Methods: Databases PubMed, CENTRAL, medRxiv, and clinicaltrials.gov were searched. Studies were included if they were placebo-controlled clinical trials and reported the safety profile and/or effectiveness of COVID-19 vaccines. The quality of the included studies was assessed using the Revised Cochrane risk-of-bias tool for randomized trials and the Revised Cochrane risk-of-bias tool for nonrandomized trials.
Results: Forty-nine clinical trials that included 421,173 participants and assessed 28 vaccines were included in this network meta-analysis. The network meta-analysis showed that Pfizer is the most effective in preventing COVID-19 infection whereas the Sputnik Vaccine was the most effective in preventing severe COVID-19 infection. In terms of the local and systemic side, the Sinopharm and V-01 vaccines were the safest.
Conclusion: We found that almost all of the vaccines included in this study crossed the threshold of 50% efficacy. However, some of them did not reach the previously mentioned threshold against the B.1.351 variant while the remainder have not yet investigated vaccine efficacy against this variant. Since each vaccine has its own strong and weak points, we strongly advocate continued vaccination efforts in individualized manner that recommend the best vaccine for each group in the community which is abundantly required to save lives and to avert the emergence of future variants.
(© 2022 Chinese Cochrane Center, West China Hospital of Sichuan University and John Wiley & Sons Australia, Ltd.)
Databáze: MEDLINE
Externí odkaz: